TSRA-196 human AAT biomarker data
The planned TSRA-196 Phase 1/2 design follows safety and biomarkers of AAT expression/function after a single infusion. These measurements provide an observable clinical-development milestone.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
First clinical data — date unconfirmed
Company context
Opened 2026 Metagenomi annual report, PDF pages 15 and 47: its competitor discussion explicitly describes Tessera as a privately-held company. Positive SEC-filed disclosure, not absence of an IPO search result. It is a 2026 annual-report statement rather than an independent October 31 registry audit; exact filing day was not independently extracted.
Potential outcome market
Will Tessera publicly report treated-human safety and functional-AAT results for TSRA-196 by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.